Filtered By:
Condition: Alopecia
Drug: Docetaxel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
CONCLUSION: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available.PMID:37196429 | DOI:10.1200/JCO.22.02546
Source: Clinical Lung Cancer - May 17, 2023 Category: Cancer & Oncology Authors: Nasser Hanna Frances A Shepherd Frank V Fossella Jose R Pereira Filippo De Marinis Joachim von Pawel Ulrich Gatzemeier Thomas Chang Yao Tsao Miklos Pless Thomas Muller Hong-Liang Lim Christopher Desch Klara Szondy Radj Gervais None Shaharyar Christian Man Source Type: research
Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
CONCLUSION: Neoadjuvant BEV plus DCC chemotherapy presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC.PMID:35647008 | PMC:PMC9130594 | DOI:10.3389/fsurg.2022.842828
Source: Cancer Control - June 1, 2022 Category: Cancer & Oncology Authors: Deguo Yu Zhenfeng Wang Tingbang He Lijun Yang Source Type: research
A case report on cannabinoid hyperemesis syndrome in palliative care: how good intentions can go wrong
CONCLUSION: Successful recognition and management of cannabinoid hyperemesis syndrome is especially important in individuals with co-morbid disorders in order to avoid cannabis toxicity.PMID:35504245 | DOI:10.1159/000524746
Source: Cancer Control - May 3, 2022 Category: Cancer & Oncology Authors: Helen Senderovich Sarah Waicus Source Type: research
A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere < sup > Ⓡ < /sup > (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy
CONCLUSIONS: The findings of this open-label, observational, multicenter, postmarketing surveillance showed that Alvotere appears to have an acceptable safety profile in Iranian cancer patients receiving chemotherapeutic regimens. (Curr Ther Res Clin Exp. 2022; 82:XXX-XXX) © 2022 Elsevier HS Journals, Inc.PMID:35035631 | PMC:PMC8749121 | DOI:10.1016/j.curtheres.2021.100659
Source: Clinical Breast Cancer - January 17, 2022 Category: Cancer & Oncology Authors: Farhad Shahi Farahnaz Vafaeezadeh Nafiseh Ansarinejad Alireza Ahmadi Ali Shahriari-Ahmadi Alireza Ghazizadeh Hassanali Vahedian Ardakani Mohammad Reza Ravanbod Sharareh Seifi Mohammad Foratyazdi Seyed Asadollah Mousavi Mansour Rajabi Vahid Hossein Rahimi Source Type: research
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India
CONCLUSIONS: Preoperative chemotherapy with a taxane-based triple-drug regimen is a reasonable approach in squamous cell carcinoma of the esophagus, associated with improvement in complete pathological response rates, increases complete resection rates, with manageable toxicity.PMID:34674048 | DOI:10.1186/s43046-021-00094-0
Source: J Egypt Natl Canc In... - October 21, 2021 Category: Cancer & Oncology Authors: Partha Sarathi Roy Gaurav Kumar Sreya Mallik Satya Sadhan Sarangi Bhargab Jyoti Saikia Munlima Hazarika Abhijit Talukdar Source Type: research
FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news
